Kai Shao

ORCID: 0000-0002-1355-8463
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Dementia and Cognitive Impairment Research
  • Stroke Rehabilitation and Recovery
  • Alzheimer's disease research and treatments
  • Complement system in diseases
  • Neurobiology of Language and Bilingualism
  • Spatial Neglect and Hemispheric Dysfunction
  • Acute Ischemic Stroke Management
  • Neurological Disease Mechanisms and Treatments
  • Functional Brain Connectivity Studies
  • Infectious Diseases and Tuberculosis
  • Memory and Neural Mechanisms
  • Neuroinflammation and Neurodegeneration Mechanisms
  • Vascular Malformations Diagnosis and Treatment
  • Cerebral Venous Sinus Thrombosis
  • Cardiovascular Function and Risk Factors
  • Liver Disease Diagnosis and Treatment
  • Lipid metabolism and disorders
  • MicroRNA in disease regulation
  • Ginseng Biological Effects and Applications
  • Inflammation biomarkers and pathways
  • Leprosy Research and Treatment
  • Blood Coagulation and Thrombosis Mechanisms
  • Intracranial Aneurysms: Treatment and Complications
  • Health, Environment, Cognitive Aging
  • Cardiac Fibrosis and Remodeling

German Center for Neurodegenerative Diseases
2023-2024

Capital Medical University
2022-2024

University of Cologne
2024

University of Bonn
2024

Soochow University
2020-2021

First Affiliated Hospital of Soochow University
2020-2021

Hebei Medical University
2020

Hebei General Hospital
2019-2020

To explore the complementary relationship between magnetic resonance imaging (MRI) radiomic and plasma biomarkers in early diagnosis conversion prediction of Alzheimer’s disease (AD), our study aims to develop an innovative multivariable model that integrates those two for predicting results AD. This longitudinal multicentric cohort included 2 independent cohorts: Sino Longitudinal Study on Cognitive Decline (SILCODE) project Alzheimer Disease Neuroimaging Initiative (ADNI). We collected...

10.34133/research.0354 article EN cc-by Research 2024-01-01

Abstract INTRODUCTION Subjective cognitive decline (SCD) in amyloid‐positive (Aβ+) individuals was proposed as a clinical indicator of Stage 2 the Alzheimer's disease (AD) continuum, but this requires further validation across cultures, measures, and recruitment strategies. METHODS Eight hundred twenty‐one participants from SILCODE DELCODE cohorts, including normal controls (NC) with SCD recruited community or memory clinics, underwent neuropsychological assessments over up to 6 years....

10.1002/alz.14119 article EN cc-by-nc-nd Alzheimer s & Dementia 2024-07-27

Introduction The clock-drawing test (CDT) has been used as a screening tool to identify cognitive deficit in patients with dementia. However, it not extensively evaluated for categorizing vascular mild impairment (vMCI). This study aimed examine the discrimination of vMCI using various CDT scoring methods.Method A total 120 and 119 normal control (NC) subjects were tested three quantitative systems: one from Montreal Cognitive Assessment (MoCA) (CDT3) systems Rouleau (CDT10) Babins (CDT18)....

10.1080/13803395.2020.1793104 article EN Journal of Clinical and Experimental Neuropsychology 2020-07-02

Abstract Introduction Subjective cognitive decline (SCD) is proposed to indicate transitional stage-2 in the AD continuum, yet longitudinal fluid biomarker data for this stage scarce. We investigated if blood-based biomarkers amyloid-positive individuals with SCD (A+SCD) support as distinct from stages-1 and -3 identify those at high risk progression. Methods analyzed plasma phospho-tau-181 (p181) neurofilament-light-chain (NfL) a prospective multicenter study of 460 participants across...

10.1101/2024.07.10.24310205 preprint EN 2024-07-10

To investigate the roles of microRNA-21 (miR-21) in pathogenesis non-alcoholic fatty liver disease (NAFLD) with high-fat diet-induced insulin resistance (IR) and diabetes mellitus (DM) mice model.Eight-week-old C57BL/6 were allocated into control group, IR DM group. Body mass was recorded. Intraperitoneal glucose tolerance test performed to determine any abnormal metabolism. The pathological changes detected by biopsy. Changes free blood glucose, serum insulin, fat tumor necrosis factor Α...

10.3881/j.issn.1000-503x.2016.02.004 article EN PubMed 2016-04-01

The clock-drawing test (CDT) is a widely used screening tool for detecting cognitive decline. However, normative data Chinese individuals are scarce. Our study aimed to provide standardized values the three quantitative CDT scoring methods that were tailored Chinese-speaking adults in Shijiazhuang City and explore discriminant validity of scores patients with acute ischemic stroke.We conducted among 418 healthy aged between 35 84 years. was administered scored by five raters using method...

10.1002/brb3.1806 article EN cc-by Brain and Behavior 2020-08-27

The anterior-temporal (AT) and posterior-medial (PM) networks have been proposed to play pivotal roles in the memory processing associated with Alzheimer's disease (AD). Nevertheless, these two networks' intrinsic functional coupling characteristics are still vague different AD stages.

10.1177/13872877241291236 article EN Journal of Alzheimer s Disease 2024-11-15

Abstract Background Subjective cognitive decline (SCD), in the absence of objective impairment, may be first symptomatic manifestation Alzheimer's disease (AD). Previous studies have suggested that its combination with amyloid‐positivity (Aβ+) represent stage 2 AD, and is associated a higher risk future decline. Here, we aim to (1) confirm this using plasma Aβ42/40 ratio, (2) test whether addition phospho‐tau181 (ptau 181 , marker Aβ tau pathology) could help refine prediction SCD patients....

10.1002/alz.086729 article EN cc-by Alzheimer s & Dementia 2024-12-01

Abstract Background Cognitively unimpaired (CU) older adults with abnormal levels of β‐amyloid (Aβ) deposition are considered in the preclinical stage Alzheimer’s disease (AD) and, when combined subjective cognitive decline (SCD), proposed as 2 AD NIA‐AA framework. Here, we aim to investigate whether neuropathologic deterioration increases early stages, particularly AD. Method We included 341 CU participants over 50 years age from Sino Longitudinal Study on Cognitive Decline (SILCODE) study....

10.1002/alz.091100 article EN cc-by Alzheimer s & Dementia 2024-12-01

To the Editor: Bilateral thalamic lesions are uncommon, but different types of pathogenesis can be classified into metabolic processes, toxic exposures, infection, vascular lesions, and tumors.[1] Among possible forms pathogenesis, intracranial dural arteriovenous fistula (dAVF) is extremely rare.[1] Several articles have reported on cases bilateral associated with dAVFs. However, due to differences in supply arteries drainage veins that were involved, as well treatment methods used, dAVFs...

10.1097/cm9.0000000000001115 article EN cc-by-nc-nd Chinese Medical Journal 2020-09-17

Abstract Objective: Previous studies demonstrated that diabetic stroke patient had a poor prognosis and excess activation of the complement system in peripheral blood. In this study, association serum levels with was examined. Methods: Patients acute ischemic were recruited divided into two groups according to history diabetes. Baseline data on admission including C3 C4 collected. Neurologic function at discharge primary outcome quantified by National Institutes Health Stroke Scale (NIHSS)....

10.21203/rs.3.rs-274699/v1 preprint EN cc-by Research Square (Research Square) 2021-03-19

Abstract Background Subjective cognitive decline (SCD) is supposed to appear early in the course of Alzheimer’s Disease (AD). Although subtle deficits and psychiatric symptoms have been described SCD, their association with amyloid pathology still unclear. Method We collected SCD normal controls (NC) from Sino Longitudinal Study on Cognitive Decline (SILCODE), a Chinese longitudinal observational study, which aims develop risk prediction models conversion mild impairment individuals SCD....

10.1002/alz.077056 article EN Alzheimer s & Dementia 2023-12-01
Coming Soon ...